The present invention relates to the use of a composition that increases central nervous system GABA levels in a mammal, for the treatment of addiction to drugs of abuse and modification of behavior associated with addiction to drugs of abuse in said mammal.

According to the present invention there is provided fragrance compositions comprising (a) fragrance; and (b) cyclic oligosaccharides having one or more unsubstituted alkyl substituents; wherein the weight ratio of (a) to (b) is at least about 1:1. The compositions of the present invention provide a long-lasting fragrance while at the same time having a `burst` of fragrance on application.

The compounds of formula I-IV: ##STR1## wherein n is an integer of from 1 to 4, or pharmaceutically acceptable salts thereof are useful to prevent and treat visceral pain and gastrointestinal disorders.

Duplex polynucleotides containing damage or errors are detected with hindered intercalating compounds which are capable of intercalating only in the presence of such damage or error. Conditions characterized by the presence of polynucleotide errors or damage are treated with such compounds that are capable of catalyzing polynucleotide cleavage with light. Suitable compound include compounds of the formula: where R.sub.1 and R.sub.2 are each independently aryl, heteroaryl, substituted aryl or sub...

There is provided a natural composition for boosting the libido of an individual, the composition including an effective amount of an aphrodisiac and a compound to increase blood flow to the pelvic area in a pharmaceutically acceptable carrier. A natural composition for boosting the libido of an individual, including an effective amount of a compound for driving blood flow to the penis and an aphrodisiac in a pharmaceutically acceptable carrier is also provided. Also provided is a method of incr...

The invention relates to the field of antiviral agents, and more specifically to antiviral therapy. The invention provides use of at least one compound or mixture of compounds of the general formula ##STR1## or a functional equivalent or pharmaceutically acceptable salt or hydrate thereof for the production of a pharmaceutical composition for the treatment of a viral infection.

Pharmaceutical compositions for oral administration comprising a cyclosporin or macrolide as active ingredient, and a polyethoxylated saturated hydroxy-fatty acid.

The use of polymers obtainable by free-radical polymerization of a) at least one vinyl ester of C.sub.1 -C.sub.24 -carboxylic acids in the presence of b) polyether-containing compounds and c) optionally one or more other copolymerizable monomers and subsequent at least partial hydrolysis of the ester functions of the original monomers a), in hair cosmetic formulations.

A flaky, fine powder comprising a flaky substance as the base and silica particles covering the surface of the base, aimed at reducing the glossiness of the base caused by the irregular reflection of light on its surface and improving the slipperiness. In particular, the powder comprises a flaky base substance such as natural mica and silica particles deposited on the base surface, wherein the silica particles may be optionally further immobilized by the hydrolysate of alkoxysilane or silica gel...

The present invention relates to use of compounds represented by the following general formula [1] or salts or prodrugs thereof: ##STR1## [where R.sup.1 represents hydrogen atom or lower alkoxy group; R.sup.2 represents hydrogen atom, lower alkoxy group, optionally substituted phenyl group, ##STR2## (where R.sup.3 represents acyl group); X represents --CO-- or --CH.sub.2 --; and n-represents 1 or 2], as drugs for overcoming a resistance to anticancer drugs or drugs for enhancing an effect of ant...